Medical Course and Complications After Heart Transplantation

  • Ranjan RayEmail author
  • Michael Pham


Heart transplantation prolongs lives and offers an average survival of 10 years. The transplanted heart is denervated; thus it takes some time for patients to acclimate to the new way their heart operates. After a heart transplant, patients are maintained on aggressive immunosuppression to prevent rejection. However, immunosuppressive medications are associated with their own risks, such as metabolic complications, kidney dysfunction, infection and malignancy. Despite immunosuppression, patients can experience rejection, and chronic cardiac allograft vasculopathy. Management of heart transplant recipients requires effective multidisciplinary teams and communication between the patients, the caregivers, and the transplant team.


Heart failure End-stage heart disease Heart transplantation Outcomes Rejection Immunosuppressant Survival 


  1. 1.
    Lund LH, Edwards LB, Dipchang AI, et al. Registry of the International Society for Heart and Lung Transplantation: thirty-third official adult heart transplant report – 2016. J Heart Lung Transplant. 2016;35(10):1158–69.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Lower RR, Shumway NE. Studies on orthotopic homotransplantation of the canine heart. Surg Forum. 1960;11:18–9.PubMedGoogle Scholar
  3. 3.
    Dreyfus G, Jebara V, Mihaileanu S, Carpentier AF. Total orthotopic heart transplantation: an alternative to the standard technique. Ann Thorac Surg. 1991;52(5):1181–4.PubMedCrossRefGoogle Scholar
  4. 4.
    El-Gamel A, Deiraniya AK, Rahman AN, Campbell CS, Yonan NA. Orthotopic heart transplantation hemodynamics: does atrial preservation improve cardiac output after transplantation? J Heart Lung Transplant. 1996;15(6):564–71.PubMedGoogle Scholar
  5. 5.
    Traversi E, Pozzoli M, Grande A, et al. The bicaval anastomosis technique for orthotopic heart transplantation yields better atrial function than the standard technique: an echocardiographic automatic boundary detection study. J Heart Lung Transplant. 1998;17(11):1065–74.PubMedGoogle Scholar
  6. 6.
    Meyer SR, Modry DL, Bainey K, et al. Declining need for permanent pacemaker insertion with the bicaval technique of orthotopic heart transplantation. Can J Cardiol. 2005;21(2):159–63.PubMedGoogle Scholar
  7. 7.
    Angermann CE, Bullinger M, Spes CH, Zellner M, Kemkes BM, Theisen K. Quality of life in long-term survivors of orthotopic heart transplantation. Z Kardiol. 1992;81(8):411–7.PubMedGoogle Scholar
  8. 8.
    Jones BM, Taylor F, Downs K, Spratt P. Longitudinal study of quality of life and psychological adjustment after cardiac transplantation. Med J Aust. 1992;157(1):24–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Salyer J, Flattery MP, Joyner PL, Elswick RK. Lifestyle and quality of life in long-term cardiac transplant recipients. J Heart Lung Transplant. 2003;22(3):309–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients – a large European trial. Am J Transplant. 2006;6(6):1387–97.PubMedCrossRefGoogle Scholar
  11. 11.
    Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6(6):1377–86.PubMedCrossRefGoogle Scholar
  12. 12.
    Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 1999;18(4):336–45.PubMedCrossRefGoogle Scholar
  13. 13.
    Ye F, Ying-Bin X, Yu-Guo W, Hetzer R. Tacrolimus versus cyclosporine microemulsion for heart transplant recipients: a meta-analysis. J Heart Lung Transplant. 2009;28(1):58–66.PubMedCrossRefGoogle Scholar
  14. 14.
    Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006;56(1):11–25; quiz 49–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med. 1989;321(16):1080–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med. 1982;306(15):913–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation. 2005;80(12):1692–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer. 2005;104(8):1661–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Kemnitz J, Cremer J, Restrepo-Specht I, et al. Hyperacute rejection in heart allografts. Case studies. Pathol Res Pract. 1991;187(1):23–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Eng J Med. 2005;352(26):2705–13.CrossRefGoogle Scholar
  21. 21.
    Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24(11):1710–20.PubMedCrossRefGoogle Scholar
  22. 22.
    Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22(1):58–69.PubMedCrossRefGoogle Scholar
  23. 23.
    Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998;66(4):507–15.PubMedCrossRefGoogle Scholar
  24. 24.
    Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant. 1989;8(6):430–43.PubMedGoogle Scholar
  25. 25.
    Subherwal S, Kobashigawa JA, Cogert G, Patel J, Espejo M, Oeser B. Incidence of acute cellular rejection and non-cellular rejection in cardiac transplantation. Transplant Proc. 2004;36(10):3171–2.PubMedCrossRefGoogle Scholar
  26. 26.
    Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25(2):153–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Taylor DO, Yowell RL, Kfoury AG, Hammond EH, Renlund DG. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant. 2000;19(6):518–21.PubMedCrossRefGoogle Scholar
  28. 28.
    Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006;6(1):150–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Pham MX, Deng MC, Kfoury AG, Teuteberg JJ, Starling RC, Valantine H. Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the Invasive Monitoring Attenuation Through Gene Expression (IMAGE) trial. J Heart Lung Transplant. 2007;26(8):808–14.PubMedCrossRefGoogle Scholar
  30. 30.
    Sethi GK, Kosaraju S, Arabia FA, Roasdo LJ, McCarthy MS, Copeland JG. Is it necessary to perform surveillance endomyocardial biopsies in heart transplant recipients? J Heart Lung Transplant. 1995;14(6 Pt 1):1047–51.PubMedGoogle Scholar
  31. 31.
    White JA, Guiraudon C, Pflugfelder PW, Kostuk WJ. Routine surveillance myocardial biopsies are unnecessary beyond one year after heart transplantation. J Heart Lung Transplant. 1995;14(6 Pt 1):1052–6.PubMedGoogle Scholar
  32. 32.
    Stehlik J, Starling RC, Movsesian MA, et al. Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis. J Heart Lung Transplant. 2006;25(12):1402–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Cantarovich M, Latter DA, Loertscher R. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. Clin Transpl. 1997;11(4):316–21.Google Scholar
  34. 34.
    Keren A, Hayes HM, O'Driscoll G. Late humoral rejection in a cardiac transplant recipient treated with the anti-CD20 monoclonal antibody rituximab. Transplant Proc. 2006;38(5):1520–2.PubMedCrossRefGoogle Scholar
  35. 35.
    Garrett HE Jr, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant. 2005;24(9):1337–42.PubMedCrossRefGoogle Scholar
  36. 36.
    Crespo-Leiro MG, Veiga-Barreiro A, Domenech N, et al. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management, and the value of C4d for diagnosis. Am J Transplant. 2005;5(10):2560–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Hunt SA, Strober S, Hoppe RT, Stinson EB. Total lymphoid irradiation for treatment of intractable cardiac allograft rejection. J Heart Lung Transplant. 1991;10(2):211–6.PubMedGoogle Scholar
  38. 38.
    Levin B, Bohannon L, Warvariv V, Bry W, Collins G. Total lymphoid irradiation (TLI) in the cyclosporine era – use of TLI in resistant cardiac allograft rejection. Transplant Proc. 1989;21(1 Pt 2):1793–5.PubMedGoogle Scholar
  39. 39.
    Costanzo-Nordin MR, Grusk BB, Silver MA, et al. Reversal of recalcitrant cardiac allograft rejection with methotrexate. Circulation. 1988;78(5 Pt 2):III47–57.PubMedGoogle Scholar
  40. 40.
    Bouchart F, Gundry SR, Van Schaack-Gonzales J, et al. Methotrexate as rescue/adjunctive immunotherapy in infant and adult heart transplantation. J Heart Lung Transplant. 1993;12(3):427–33.PubMedGoogle Scholar
  41. 41.
    Dein JR, Oyer PE, Stinson EB, Starnes VA, Shumway NE. Cardiac retransplantation in the cyclosporine era. Ann Thorac Surg. 1989;48(3):350–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Radovancevic B, McGiffin DC, Kobashigawa JA, et al. Retransplantation in 7,290 primary transplant patients: a 10-year multi-institutional study. J Heart Lung Transplant. 2003;22(8):862–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Pucci AM, Forbes RD, Billingham ME. Pathologic features in long-term cardiac allografts. J Heart Transplant. 1990;9(4):339–45.PubMedGoogle Scholar
  44. 44.
    Kaye DM, Esler M, Kingwell B, McPherson G, Esmore D, Jennings G. Functional and neurochemical evidence for partial cardiac sympathetic reinnervation after cardiac transplantation in humans. Circulation. 1993;88(3):1110–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Bernardi L, Bianchini B, Spadacini G, et al. Demonstrable cardiac reinnervation after human heart transplantation by carotid baroreflex modulation of RR interval. Circulation. 1995;92(10):2895–903.PubMedCrossRefGoogle Scholar
  46. 46.
    Stark RP, McGinn AL, Wilson RF. Chest pain in cardiac-transplant recipients. Evidence of sensory reinnervation after cardiac transplantation. N Eng J Med. 1991;324(25):1791–4.CrossRefGoogle Scholar
  47. 47.
    Rickenbacher PR, Pinto FJ, Lewis NP, et al. Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation. 1995;92(12):3445–52.PubMedCrossRefGoogle Scholar
  48. 48.
    Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005;45(9):1532–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110(17):2694–700.PubMedCrossRefGoogle Scholar
  50. 50.
    Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349(9):847–58.PubMedCrossRefGoogle Scholar
  51. 51.
    Kobashigawa JA, Tobis JM, Mentzer RM, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant. 2006;6(5 Pt 1):993–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Keogh AM, Valantine HA, Hunt SA, et al. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant. 1992;11(5):892–901.PubMedGoogle Scholar
  53. 53.
    Schroeder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Eng J Med. 1993;328(3):164–70.CrossRefGoogle Scholar
  54. 54.
    Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Eng J Med. 1995;333(10):621–7.CrossRefGoogle Scholar
  55. 55.
    Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997;96(5):1398–402.PubMedCrossRefGoogle Scholar
  56. 56.
    Bader FM, Kfoury AG, Gilbert EM, et al. Percutaneous coronary interventions with stents in cardiac transplant recipients. J Heart Lung Transplant. 2006;25(3):298–301.PubMedCrossRefGoogle Scholar
  57. 57.
    Halle AA 3rd, DiSciascio G, Massin EK, et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol. 1995;26(1):120–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Topkara VK, Dang NC, John R, et al. A decade experience of cardiac retransplantation in adult recipients. J Heart Lung Transplant. 2005;24(11):1745–50.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Center for Advanced Heart Failure TherapiesPalo Alto Foundation Medical GroupSan FranciscoUSA

Personalised recommendations